CY1109387T1 - Εξασθενημενα sp12 μεταλλαγματα σαλμονελας σαν αντιγονικοι φορεις - Google Patents

Εξασθενημενα sp12 μεταλλαγματα σαλμονελας σαν αντιγονικοι φορεις

Info

Publication number
CY1109387T1
CY1109387T1 CY20081101270T CY081101270T CY1109387T1 CY 1109387 T1 CY1109387 T1 CY 1109387T1 CY 20081101270 T CY20081101270 T CY 20081101270T CY 081101270 T CY081101270 T CY 081101270T CY 1109387 T1 CY1109387 T1 CY 1109387T1
Authority
CY
Cyprus
Prior art keywords
nucleic acid
cell
acid molecule
faded
inactivated
Prior art date
Application number
CY20081101270T
Other languages
English (en)
Inventor
Michael Hensel
Carlos Alberto Guzman
Eva Medina
Heiko Apfel
Christoph Hueck
David William Holden
Jacqueline Elizabeth Shea
Original Assignee
Emergent Product Development Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Development Uk Limited filed Critical Emergent Product Development Uk Limited
Publication of CY1109387T1 publication Critical patent/CY1109387T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με εμβόλια, συγκεκριμένα, με ένα εξασθενημένο gram αρνητικό κύτταρο που περιέχει το γονιδιακό τόπο SPI2, όπου τουλάχιστον ένα γονίδιο του SPI2 τόπου είναι απενεργοποιημένο / αδρανοποιημένο, όπου η εν λόγω αδρανοποίηση έχει σαν αποτέλεσμα μια εξασθένηση / μείωση της μολυσματικότητας σε σύγκριση με τον άγριο τύπο του εν λόγω κυττάρου, και (σχετίζεται) με ένα φορέα για τη παρουσίαση ενός αντιγόνου σε ένα ξενιστή, ο οποίος φορέας είναι το εν λόγω εξασθενημένο gram αρνητικό κύτταρο, όπου το εν λόγω κύτταρο περιέχει τουλάχιστον ένα ετερόλογο μόριο νουκλεϊκού οξέος περιέχοντας μια αλληλουχία νουκλεϊκού οξέος που κωδικοποιεί για το εν λόγω αντιγόνο, όπου το εν λόγω κύτταρο είναι ικανό έκφρασης του εν λόγω μορίου νουκλεϊκού οξέος ή ικανό στο να προκαλέσει την έκφραση του εν λόγω μορίου νουκλεϊκού οξέος σε ένα κύτταρο στόχο.
CY20081101270T 1998-09-04 2008-11-06 Εξασθενημενα sp12 μεταλλαγματα σαλμονελας σαν αντιγονικοι φορεις CY1109387T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98116827 1998-09-04
EP99946122A EP1108034B1 (en) 1998-09-04 1999-09-03 Attenuated salmonella spi2 mutants as antigen carriers

Publications (1)

Publication Number Publication Date
CY1109387T1 true CY1109387T1 (el) 2014-07-02

Family

ID=8232583

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101270T CY1109387T1 (el) 1998-09-04 2008-11-06 Εξασθενημενα sp12 μεταλλαγματα σαλμονελας σαν αντιγονικοι φορεις

Country Status (13)

Country Link
US (3) US6936425B1 (el)
EP (2) EP1970449B1 (el)
JP (1) JP2002524077A (el)
AT (2) ATE486940T1 (el)
AU (1) AU5860599A (el)
BR (1) BR9914479A (el)
CA (1) CA2341349C (el)
CY (1) CY1109387T1 (el)
DE (2) DE69939264D1 (el)
DK (1) DK1108034T3 (el)
ES (2) ES2356863T3 (el)
PT (1) PT1108034E (el)
WO (1) WO2000014240A2 (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017951A2 (en) * 1994-12-09 1996-06-13 Rpms Technology Limited Identification of genes responsible for in vivo survival of microorganisms
DK1108034T3 (da) * 1998-09-04 2008-11-10 Emergent Product Dev Uk Ltd Svækkede salmonella SPI2-mutanter som antigenbærere
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
AU2003204710B2 (en) * 1999-05-10 2006-08-03 Microscience Limited Attenuated microorganisms for the treatment of infection
EP1640013A3 (en) * 2000-03-17 2007-02-21 Pharmacia & Upjohn Company LLC Inactivated Salmonella vaccines
ATE300949T1 (de) * 2000-03-17 2005-08-15 Pharmacia & Upjohn Co Llc Ssa inaktivierte salmonella impfstoffe
GB0105924D0 (en) * 2001-03-09 2001-04-25 Microscience Ltd Promoter
DE60216099D1 (de) * 2001-05-17 2006-12-28 Creatogen Ag Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
JP2008509168A (ja) 2004-08-13 2008-03-27 マーシャル，バリー，ジェー． 細菌デリバリシステム
CN1276076C (zh) * 2004-12-14 2006-09-20 华东理工大学 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
US20070134814A1 (en) * 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
US8604178B2 (en) 2006-09-18 2013-12-10 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2152883A4 (en) * 2007-05-10 2010-10-27 Univ Arizona RECOMBINANT BACTERIA COMPRISING VECTORS FOR THE EXPRESSION OF NUCLEIC ACID SEQUENCES ENCODING ANTIGENS
EP2150616A4 (en) 2007-05-10 2011-07-27 Univ Arizona REGULATED ANTIGEN SYNTHESIS AND / OR REGULATED ATTENUATION FOR IMPROVING VACCINATE IMMUNOGENICITY AND / OR SAFETY
WO2008153772A2 (en) * 2007-05-25 2008-12-18 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides
WO2009046451A1 (en) * 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting a protective immune response against c. perfringens
CN102037135A (zh) * 2007-10-30 2011-04-27 阿肯色大学评议会 增强对有鞭毛的细菌的免疫反应的组合物和方法
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
US8703153B2 (en) * 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
WO2010017383A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
WO2010048322A1 (en) * 2008-10-21 2010-04-29 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
JP4575498B2 (ja) * 2009-02-20 2010-11-04 株式会社東芝 磁気記録媒体の製造方法
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
US8518658B1 (en) * 2009-04-27 2013-08-27 University Of South Florida ATP-bioluminescence immunoassay
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
US8889121B2 (en) 2010-01-22 2014-11-18 The Arizona Board Of Regents For An On Behalf Of Arizona State University Bacterium comprising a regulated rfaH nucleic acid
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
JP5746333B2 (ja) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー カンピロバクター感染を減少させるワクチン及び方法
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
RU2510839C2 (ru) * 2012-05-03 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Вакцина ассоциированная против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов
RU2496518C1 (ru) * 2012-05-03 2013-10-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Способ изготовления вакцины ассоциированной против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
EP2852405B1 (en) * 2012-05-23 2019-03-13 The United States of America, as represented by The Secretary, Department of Health and Human Services Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
PT2956165T (pt) 2013-02-14 2019-11-29 Texas A & M Univ Sys Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria
WO2014144965A1 (en) * 2013-03-15 2014-09-18 Husseiny Elsayed Mohamed I Attenuated salmonella bacteria and methods of using
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US10987432B2 (en) * 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3452069A4 (en) 2016-05-03 2020-02-12 The Board of Trustees of the University of Arkansas Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP4045672A4 (en) * 2019-10-18 2023-11-22 University of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR GENERATING ENHANCED IMMUNE RESPONSES AND RAPID ANTIBODIES PRODUCTION
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2022271976A1 (en) * 2021-06-24 2022-12-29 Elanco Us Inc. Attenuated salmonella, vaccines, and delivery platform
CN114292339B (zh) * 2022-01-05 2022-08-09 武汉科前生物股份有限公司 鞭毛素突变体与非洲猪瘟抗原的融合蛋白及其应用
CN114703214A (zh) * 2022-03-03 2022-07-05 南京吉芮康生物科技研究院有限公司 一种抗丢失时空可控表达的新型质粒及其应用
WO2024061748A1 (en) * 2022-09-21 2024-03-28 Prokarium Limited Salmonella strain with chromosomally integrated landing pad

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US232165A (en) * 1880-09-14 Mechanical musical instrument
US1449502A (en) * 1921-04-23 1923-03-27 James G Diffendaffer Restraining device
US1476164A (en) * 1922-02-21 1923-12-04 Michael J Manahan Door and window shade and curtain clamp
US1903387A (en) * 1930-08-20 1933-04-04 Eaton Mfg Co Automobile heater
US2103863A (en) * 1936-12-28 1937-12-28 Woodall Industries Inc Visor construction
US2728467A (en) * 1954-01-28 1955-12-27 Glicker Herman Parking tower structure
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IN151589B (el) 1978-12-22 1983-05-28 Biogen Nv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4550081A (en) 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US5397697A (en) 1989-01-10 1995-03-14 Ciba-Geigy Corporation Identification of plant-responsive genes of bacteria
FR2664614B1 (fr) 1990-07-11 1992-10-16 Pasteur Institut Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires.
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
EP0669989A1 (en) 1991-08-22 1995-09-06 Washington University Polynucleotide probes for salmonella
AU2778992A (en) 1991-10-07 1993-05-03 Idaho Research Foundation Inc., The Genetic construct for selection of homologous recombinants on a single selective medium
US5356797A (en) 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
WO1993010246A1 (en) 1991-11-15 1993-05-27 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
EP0668779A4 (en) 1992-11-06 1996-08-21 Univ Minnesota Vaccine to protect against pasteurellosis - infection by P.multocida.
WO1994026933A1 (en) 1993-05-13 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection
WO1996011708A1 (en) 1994-10-18 1996-04-25 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
WO1996017951A2 (en) 1994-12-09 1996-06-13 Rpms Technology Limited Identification of genes responsible for in vivo survival of microorganisms
US5700683A (en) 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
EP0857214A1 (en) 1995-10-16 1998-08-12 Smithkline Beecham Plc Novel saliva binding protein
AU7738396A (en) 1995-11-14 1997-06-05 General Hospital Corporation, The Salmonella secreted proteins and uses thereof
AU4070097A (en) 1996-08-16 1998-03-06 Uab Research Foundation, The Mucosal immunogens for novel vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
AU722326B2 (en) 1997-02-14 2000-07-27 Merck & Co., Inc. Polynucleotide vaccine formulations
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
GB9804809D0 (en) 1998-03-06 1998-04-29 Wallis Timothy S Attenuated salmonella:materials and methods relating thereto
US6585975B1 (en) 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
DK1108034T3 (da) 1998-09-04 2008-11-10 Emergent Product Dev Uk Ltd Svækkede salmonella SPI2-mutanter som antigenbærere
NZ527279A (en) 1998-11-09 2005-05-27 Microscience Ltd Virulence genes and proteins, and their use
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
WO2001032697A2 (en) 1999-11-05 2001-05-10 L'unite De Recherche En Biologie Moleculaire (Urbm) Des Facultes Universitaires Notre Dame De La Paix (Fundp) Virulence genes and proteins from brucella melitensis, and their use
WO2001048208A2 (en) 1999-12-23 2001-07-05 Vmax Limited Streptococcus pyogenes virulence genes and proteins and their use
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0127657D0 (en) 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria

Also Published As

Publication number Publication date
ATE486940T1 (de) 2010-11-15
EP1970449A1 (en) 2008-09-17
ATE403728T1 (de) 2008-08-15
JP2002524077A (ja) 2002-08-06
WO2000014240A2 (en) 2000-03-16
ES2356863T3 (es) 2011-04-13
EP1108034A2 (en) 2001-06-20
WO2000014240A3 (en) 2000-08-03
US7700104B2 (en) 2010-04-20
ES2313792T3 (es) 2009-03-01
US6936425B1 (en) 2005-08-30
EP1108034B1 (en) 2008-08-06
US7955600B2 (en) 2011-06-07
AU5860599A (en) 2000-03-27
PT1108034E (pt) 2008-11-14
CA2341349A1 (en) 2000-03-16
US20080075739A1 (en) 2008-03-27
BR9914479A (pt) 2001-06-26
DE69942925D1 (de) 2010-12-16
DK1108034T3 (da) 2008-11-10
CA2341349C (en) 2013-12-10
US20040203039A1 (en) 2004-10-14
DE69939264D1 (de) 2008-09-18
EP1970449B1 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
CY1109387T1 (el) Εξασθενημενα sp12 μεταλλαγματα σαλμονελας σαν αντιγονικοι φορεις
DE69806408D1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
CY1105109T1 (el) Διαδικασια για την παρασκευη μικρου μοριακου βαρους πολυαιθυλενιμινης
SE8303463D0 (sv) Nukleotidsekvens som kodar ytantigenet av hepatit b-virus, vektor innehallande nemnda nukleotidsekvens, forfarande for erhallande derav samt erhallet antigen
ES2042828T3 (es) Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores.
CY1106635T1 (el) Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια
NO904538L (no) Kimaere glykoproteiner inneholdende immunogene segmenter av humant parainfluensavirus type 3.
Vanloubbeeck et al. The immunology of Leishmania infection and the implications for vaccine development
ES2244617T3 (es) Vacunas a base de salmonelas en las cuales los genes ssa han sido inactivados.
DK1253201T3 (da) Kyllingeanæmivirusmutanter og vacciner baseret på det virale protein VP3 eller sekvenser af dette virus kodende derfor
FI861485A0 (fi) Producering av immunologiskt reaktiva virala proteiner.
ES553758A0 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia.
KR930701610A (ko) 미생물의 세포, 조직 또는 숙주 지향성을 변화시키는 방법, 이 방법으로 수득된 재조합 미생물, 및 의학 및 수의학분야에서 이들을 사용하는 방법
He et al. A homologous or variant booster vaccine after Ad26. COV2. S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques
PE72699A1 (es) Antigeno del rotavirus, vacuna y agente diagnostico para infeccion por rotavirus y un metodo para producir el antigeno
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
WO2019143921A3 (en) Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
PL341724A1 (en) Mutated newcastle disease virus (ndv) and method of obtaining same, live or inactivated vaccine containing same and method of obtaining such vaccine
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.
Mulyadi et al. IMMUNOGENICITY AND PROTECTIVITY OF THE OUTER MEMBRANE PROTEIN BANDS OF PASTEURELLA MULTOCIDA ISOLATE U-6
ES8801948A1 (es) Un procedimiento para la preparacion de un transformante que comporta un vector de expresion que comprende un gen que codifica una proteina envolvente de un virus de sida
ATE366305T1 (de) Vogel-polyomavirus impfstoff in papageien